BG105782A - Reverse hydroxamate inhibitors of matrix metalloproteinases - Google Patents
Reverse hydroxamate inhibitors of matrix metalloproteinasesInfo
- Publication number
- BG105782A BG105782A BG105782A BG10578201A BG105782A BG 105782 A BG105782 A BG 105782A BG 105782 A BG105782 A BG 105782A BG 10578201 A BG10578201 A BG 10578201A BG 105782 A BG105782 A BG 105782A
- Authority
- BG
- Bulgaria
- Prior art keywords
- matrix metalloproteinases
- hydroxamate inhibitors
- reverse hydroxamate
- inhibitors
- matrix metalloproteinase
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23908799A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/002038 WO2000044739A1 (en) | 1999-01-27 | 2000-01-27 | Reverse hydroxamate inhibitors of matrix metalloproteinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105782A true BG105782A (en) | 2002-04-30 |
Family
ID=22900549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105782A BG105782A (en) | 1999-01-27 | 2001-08-03 | Reverse hydroxamate inhibitors of matrix metalloproteinases |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20020007060A1 (enExample) |
| EP (1) | EP1147101B1 (enExample) |
| JP (1) | JP4718686B2 (enExample) |
| KR (1) | KR100748010B1 (enExample) |
| CN (1) | CN1222519C (enExample) |
| AR (1) | AR029329A1 (enExample) |
| AT (1) | ATE228122T1 (enExample) |
| AU (1) | AU764383B2 (enExample) |
| BG (1) | BG105782A (enExample) |
| BR (1) | BR0007278A (enExample) |
| CA (1) | CA2358951C (enExample) |
| CO (1) | CO5150194A1 (enExample) |
| CZ (1) | CZ20012591A3 (enExample) |
| DE (1) | DE60000819T2 (enExample) |
| DK (1) | DK1147101T3 (enExample) |
| ES (1) | ES2187443T3 (enExample) |
| HK (1) | HK1043115A1 (enExample) |
| HU (1) | HUP0105477A2 (enExample) |
| IL (1) | IL143713A0 (enExample) |
| NO (1) | NO20013669L (enExample) |
| NZ (1) | NZ512372A (enExample) |
| PL (1) | PL349771A1 (enExample) |
| PT (1) | PT1147101E (enExample) |
| SK (1) | SK10582001A3 (enExample) |
| TR (1) | TR200102159T2 (enExample) |
| TW (1) | TWI225486B (enExample) |
| WO (1) | WO2000044739A1 (enExample) |
| ZA (1) | ZA200104979B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| AU2001298065A1 (en) * | 2001-01-12 | 2003-09-02 | Abbott Laboratories | Process for the preparation of matrix metalloproteinase inhibitors |
| EP1431285B1 (en) | 2001-09-07 | 2009-01-07 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
| EP1896404B1 (en) * | 2005-06-27 | 2014-09-17 | Nabriva Therapeutics AG | Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group |
| US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| WO2015107139A1 (en) | 2014-01-17 | 2015-07-23 | Proyecto De Biomedicina Cima, S.L. | Compounds for use as antifibrinolytic agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0780386B1 (en) * | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
-
2000
- 2000-01-25 CO CO00003867A patent/CO5150194A1/es unknown
- 2000-01-26 AR ARP000100349A patent/AR029329A1/es not_active Application Discontinuation
- 2000-01-27 ES ES00905758T patent/ES2187443T3/es not_active Expired - Lifetime
- 2000-01-27 SK SK1058-2001A patent/SK10582001A3/sk unknown
- 2000-01-27 WO PCT/US2000/002038 patent/WO2000044739A1/en not_active Ceased
- 2000-01-27 CZ CZ20012591A patent/CZ20012591A3/cs unknown
- 2000-01-27 TR TR2001/02159T patent/TR200102159T2/xx unknown
- 2000-01-27 PT PT00905758T patent/PT1147101E/pt unknown
- 2000-01-27 NZ NZ512372A patent/NZ512372A/xx unknown
- 2000-01-27 AU AU27391/00A patent/AU764383B2/en not_active Ceased
- 2000-01-27 EP EP00905758A patent/EP1147101B1/en not_active Expired - Lifetime
- 2000-01-27 HK HK02102947.8A patent/HK1043115A1/zh unknown
- 2000-01-27 CA CA002358951A patent/CA2358951C/en not_active Expired - Fee Related
- 2000-01-27 CN CNB008032378A patent/CN1222519C/zh not_active Expired - Fee Related
- 2000-01-27 JP JP2000595995A patent/JP4718686B2/ja not_active Expired - Fee Related
- 2000-01-27 DK DK00905758T patent/DK1147101T3/da active
- 2000-01-27 HU HU0105477A patent/HUP0105477A2/hu unknown
- 2000-01-27 IL IL14371300A patent/IL143713A0/xx unknown
- 2000-01-27 KR KR1020017009393A patent/KR100748010B1/ko not_active Expired - Fee Related
- 2000-01-27 PL PL00349771A patent/PL349771A1/xx not_active Application Discontinuation
- 2000-01-27 DE DE60000819T patent/DE60000819T2/de not_active Expired - Lifetime
- 2000-01-27 AT AT00905758T patent/ATE228122T1/de not_active IP Right Cessation
- 2000-01-27 BR BR0007278-8A patent/BR0007278A/pt not_active Application Discontinuation
- 2000-02-25 TW TW089101383A patent/TWI225486B/zh not_active IP Right Cessation
-
2001
- 2001-06-18 ZA ZA200104979A patent/ZA200104979B/en unknown
- 2001-07-16 US US09/905,242 patent/US20020007060A1/en not_active Abandoned
- 2001-07-26 NO NO20013669A patent/NO20013669L/no not_active Application Discontinuation
- 2001-08-03 BG BG105782A patent/BG105782A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL133369A0 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
| IL141410A0 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) | |
| NZ516562A (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
| MX9804623A (es) | Precursores inactivos de farmacos inhibidores de trombina. | |
| GEP20032920B (en) | Inhibitors of Phospholipase Enzymes | |
| CA2260337A1 (en) | Therapeutic agents | |
| TW200510368A (en) | Pharmaceutical compositions and combinations of novel non-imidazole compounds | |
| AU5414000A (en) | Compounds | |
| SE9602646D0 (sv) | Pharmaceutically-useful compounds | |
| GB9715030D0 (en) | Metalloproteinase inhibitors | |
| NZ331484A (en) | Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases | |
| CA2352054A1 (en) | New amidino derivatives and their use as thrombin inhibitors | |
| MY128164A (en) | Compounds | |
| BG104575A (en) | Matrix metalloprotease inhibitors | |
| BG105782A (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
| GB2324091A (en) | Metalloproteinase inhibitors | |
| AU8039501A (en) | New amidino derivatives and their use as thrombin inhibitors | |
| MY133842A (en) | Sodium-hydrogen exchanger type 1 inhibitor. | |
| BG105252A (en) | Isoquinolines as urokinase inhibitors | |
| WO2004006927A3 (en) | Sulphonylpiperidine derivatives containing an alkenyl or alkynly moiety for use as matrix metalloproteinase inhibitors | |
| DE60012208D1 (de) | Type 1 inhibitorkristalle als inhibitoren des natrium-protonen austauschs |